Effectiveness and Safety of ONUREG (Oral Azacitidine) in Chinese Patients With Acute Myeloid Leukemia

Official record

Identifier

NCT07458542

Recruiting locations

country

China

Interventions studied

Azacitidine

Lead sponsor

Bristol-Myers Squibb

Target enrolment

44 participants

Study type

OBSERVATIONAL

Phase

Not provided in the official record

Status

Completed

First posted

Mar 9, 2026

Last updated on the registry

Oct 1, 2026

Age

18 Years

Sex

ALL

Study contact

No public contact is listed on the official record.

Eligibility criteria

Reproduced verbatim from the official record. Eligibility is decided by the study team, never by this page.

Inclusion Criteria:

* Documented diagnosis of Acute Myeloid Leukemia (AML).
* Achieved first complete response (CR) or complete response with incomplete blood recovery (CRi) following intensive induction chemotherapy.
* Not able or unwilling to undergo Hematopoietic Stem Cell Transplantation (HSCT).
* Received oral azacitidine as maintenance therapy after first CR or CRi following intensive induction chemotherapy in real-world settings (Note: CR/CRi status at oral azacitidine treatment initiation is left to the judgment of the local clinicians depending on the treatment response and the condition of the patient in routine clinical practices).
* Age ≥ 18 years at the index date (oral azacitidine initiation date).

Exclusion Criteria:

• Evidence of relapse prior to oral azacitidine initiation recorded in electronic health record (EHR).

Indexed under

Leukemia